Form 6-K NOVO NORDISK A S For: Sep 28

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

________________

 

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER

 

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

September 28, 2026

________________

 

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

 

 

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

________________

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

 

Form 20-F ☒

Form 40-F ☐

  

 

 

 

 

 

Novo Nordisk A/S – Share repurchase programme

 

Bagsværd, Denmark, 28 September 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

 

Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.

 

Since the announcement 21 September, the following transactions have been made:

 

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	19,415,000		5,829,922,946
21 September 2026	250,000	267.41	66,853,084
22 September 2026	250,000	258.30	64,575,341
23 September 2026	220,000	256.17	56,357,077
24 September 2026	240,000	250.42	60,101,974
25 September 2026	245,000	253.19	62,031,620
Accumulated under the programme	20,620,000		6,139,842,042

 

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

 

With the transactions stated above, Novo Nordisk owns a total of 49,419,876 B shares of DKK 0.10 as treasury shares, corresponding to 1.1% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

 

Page 2 of 2

 

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 25 September 2026, Novo Nordisk has since 4 February 2026 repurchased a total 3 5,379,179 B shares at an average share price of DKK 280.95 per B share equal to a transaction value of DKK 9,939,842,031.

 

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

 

Contacts for further information

 

Novo Nordisk Media:
Ambre James-Brown	Liz Skrbkova (US)
+45 3079 9289	+1 609 917 0632
[email protected]	[email protected]
Novo Nordisk Investors:
Michael Novod	Sina Meyer
+45 3075 6050	+45 3079 6656
[email protected]	[email protected]

 

Christoffer Togo Solgaard-Tullin
+45 3079 1471
[email protected]
Ida Schaap Melvold	Mads Berner Bruun
+45 3077 5649	+45 3075 2936
[email protected]	[email protected]
Frederik Taylor Pitter (US)	Alex Bruce (US)
+1 609 613 0568	+1 640 230 0276
[email protected]	[email protected]

 

 

 

Novo Nordisk A/S Investor Relations	Novo Allé 1 2880 Bagsværd Denmark	Telephone: +45 4444 8888	www.novonordisk.com CVR no: 24 25 67 90
			Company announcement No 58 / 2026

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

 

Date: September 28, 2026

NOVO NORDISK A/S   Maziar Mike Doustdar Chief Executive Officer

 

 

 

 

 

 

 

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Novo Nordisk Wegovy data shows liver fat reduction in obesity trial
• Alta Group Remodeling CEO Leo Lutskov Explains Why AI Cannot Replace an Experienced Remodeling Professional
• NJ Primary Care Urges Jersey City Women to Start Mammograms at 40 Under Updated National Guidelines